Company Encyclopedia
View More
name
Fangsheng Pharmaceutical
603998.SH
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infective drugs. The company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), and Qiangli Loquat Dew and others.
3.051 T
603998.SHMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking145/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE18.08%A
    • Profit Margin17.55%A
    • Gross Margin73.40%A
  • Growth ScoreD
    • Revenue YoY-4.47%D
    • Net Profit YoY8.21%C
    • Total Assets YoY-7.75%D
    • Net Assets YoY2.39%C
  • Cash ScoreC
    • Cash Flow Margin569.76%C
    • OCF YoY-4.47%D
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreC
    • Gearing Ratio42.20%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fangsheng Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 268 million yuan, a year-on-year increase of 17.6%

    According to the Zhitong Finance APP, Fangsheng Pharmaceutical disclosed its third-quarter report for 2025. The company achieved revenue of 1.253 billion yuan in the first three quarters, a year-on-year decrease of 7.02%; the net profit attributable to shareholders of the listed company was 268 million yuan, a year-on-year increase of 17.6%; the net profit excluding non-recurring gains and losses was 213 million yuan, a year-on-year increase of 30.54%; the basic earnings per share were 0.61 yuan

    Zhitong·
    SH
    603998
    +1.62%
    Zhitong·
    SH
    603998
    +1.62%

    Fangsheng Pharmaceutical: Clinical trial for Relugolix tablets approved

    According to the Zhitong Finance APP, Fangsheng Pharmaceutical announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng"), has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, approving the clinical trial of this product for prostate cancer

    Zhitong·
    SH
    603998
    +1.62%
    Zhitong·
    SH
    603998
    +1.62%

    Fangsheng Pharmaceutical plans to acquire the marketing authorization for "Compound Acetate Dexamethasone Cream."

    Fangsheng Pharmaceutical announced that it has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream." This move aims to enrich the company's product line, promote the development strategy of innovative traditional Chinese medicine, and is expected to bring new profit growth points to the company, enhancing its market competitiveness

    Zhitong·
    SH
    603998
    +1.62%
    Zhitong·
    SH
    603998
    +1.62%

    Fangsheng Pharmaceutical: The summary report of the Phase II clinical trial for Zhilong Tongluo tablets has been obtained

    Fangsheng Pharmaceutical announced that its research and development of the traditional Chinese medicine innovative drug Zhilong Tongluo Pian has obtained the Phase II clinical research report. This drug is suitable for various symptoms during the recovery period of cerebral infarction, and the trial results show good safety, as well as positive effects in improving neurological function and quality of life. It is recommended to continue with Phase III clinical research

    Zhitong·
    SH
    603998
    +1.62%
    Zhitong·
    SH
    603998
    +1.62%

    Fangsheng Pharmaceutical: Clinical trial for gynecological hemostatic and analgesic granules approved

    According to the Zhitong Finance APP, Fangsheng Pharmaceutical announced that its holding subsidiary, Guangdong Fangsheng Rongo Pharmaceutical Co., Ltd. (referred to as "Fangsheng Rongo"), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its innovative traditional Chinese medicine research and development project, gynecological hemostatic and analgesic granules. The National Medical Products Administration has agreed to conduct Phase II and III clinical trials based on further improvement of the clinical trial protocol

    Zhitong·
    SH
    603998
    +1.62%
    Zhitong·
    SH
    603998
    +1.62%
    © 2025 Longbridge｜Disclaimer